CCL11

Across TCGA pan-cancer cohorts, CCL11 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CCL11’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CCL11 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CCL11 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

HNSC, KIRC, and KIRP are the cancer types where CCL11 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCL11 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	IV	+2.896	<.001	11	view →
KIRC	Male	II,III,IV	−2.268	<.001	11	view →
KIRP	Male	All	−1.660	<.001	9	view →
KICH	Female	II,III,IV	−2.698	<.001	8	view →
COAD	All	All	−0.973	<.001	7	view →
BRCA	All	All	+1.916	<.001	6	view →
LUAD	Female	II,III,IV	+1.248	.004	6	view →
THCA	All	All	+0.187	.004	5	view →
UCEC	All	All	−0.993	.016	2	view →
PRAD	All	All	+0.379	.002	2	view →
LUSC	Male	III,IV	−1.157	.021	1	view →
CHOL	All	All	+1.046	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CCL11–HNSC

Open the HNSC breakdown →